Phathom Pharmaceuticals, Inc.
6.22USD
-0.0600 (-0.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PHAT.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 0.0 | 682.0K | 55.3M | 175.1M | 315.2M | 489.4M |
| Q1 | — | 0.0 | 1.9M | 28.5M | 58.3M | 93.9M |
| Q2 | — | 0.0 | 7.3M | 39.5M | 74.3M | — |
| Q3 | — | 0.0 | 16.4M | 49.5M | 84.7M | — |
| Q4 | — | 682.0K* | 29.7M* | 57.6M* | 98.2M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -5.05 | -3.93 | -5.29 | -3.03 | -.044 | .964 |
| Q1 | -1.07 | -.890 | -1.42 | -1.31 | -.370 | .011 |
| Q2 | -1.33 | -.840 | -1.56 | -1.05 | -.210 | — |
| Q3 | -1.32 | -.760 | -1.32 | -.410 | -.160 | — |
| Q4 | -1.41* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -1.55* |
| -1.18* |
| -.290* |
| .105 |
| — |
Debt level and coverage